Tacrolimus-resistant SARS-CoV-2-specific T cell products to prevent and treat severe COVID-19 in immunosuppressed patients

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Molecular Therapy — Methods & Clinical Development

Topics

Biology

Immunology

Medicine

Internal Medicine

Neurology

Show all topics

DOI

10.1016/j.omtm.2022.02.012

License

CC-BY-NC-ND

Other Formats

PDF